Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,928 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood High Pressure Clear all
Completed Phase 4 Interventional Results available

Optimal Blood Pressure Treatment Thresholds Postpartum

NCT06069102
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Hypertension, Eclampsia, Gestational Hypertension, Cardiovascular Diseases, Toxemia, Pregnancy Complications, Vascular Diseases, Hypertension, Pregnancy Induced, Hypertension;Pre-Eclamptic
Interventions
Usual care, Tight blood pressure control
Drug
Lead sponsor
Alisse Hauspurg
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension

NCT05394766
View directory record Official record
Conditions
Hypertension
Interventions
Omada Hypertension Program
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension

NCT00332072
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 17, 2026, 10:29 PM EDT
Active, not recruiting Phase 3 Interventional

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422
View directory record Official record
Conditions
Hypertension
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Covina, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 17, 2026, 10:29 PM EDT
Active, not recruiting Not applicable Interventional

Skills-Based Educational Strategies for Reduction of Vascular Events in Orange County

NCT05641519
View directory record Official record
Conditions
Hypertension
Interventions
SERVE OC Intervention, Enhanced Standard Intervention
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
5 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

NCT00255528
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2007 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00061529
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

NCT03901781
View directory record Official record
Conditions
Ocular Hypertension
Interventions
ST266 via Intranasal Delivery
Combination Product
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
20 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 17, 2026, 10:29 PM EDT
Terminated Phase 2 Interventional

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046) Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 17, 2026, 10:29 PM EDT
Terminated Not applicable Interventional Results available

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

NCT05765253
View directory record Official record
Conditions
Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax, Vascular Diseases
Interventions
Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Device · Procedure
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Reducing Disparities in the Treatment of Hypertension Using the OWL mHealth Tool

NCT03974334
View directory record Official record
Conditions
Hypertension
Interventions
OWL-Hypertension 8 Wk Trial
Behavioral
Lead sponsor
Paula Gardiner
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 10:29 PM EDT
Terminated Phase 3 Interventional Results available

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

NCT03794583
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled treprostinil solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
28
States / cities
Birmingham, Alabama • Sacramento, California • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Translating Dietary Trials Into the Community

NCT00964483
View directory record Official record
Conditions
Hypertension
Interventions
DASH diet, Delayed Intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)

NCT01644656
View directory record Official record
Conditions
Portal Hypertension, Chronic Liver Disease
Interventions
ARFI ultrasound
Device
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D for Chemoprevention

NCT00585637
View directory record Official record
Conditions
Gastrointestinal Cancers, Prostate Cancer, Hypertension
Interventions
Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years to 80 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of L-citrulline Supplementation on Vascular Function in Metabolic Syndrome

NCT06025357
View directory record Official record
Conditions
Metabolic Syndrome, Menopause
Interventions
L-Citrulline supplementation, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
45 Years to 79 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 17, 2026, 10:29 PM EDT
Withdrawn Phase 4 Interventional

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

NCT01927406
View directory record Official record
Conditions
Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions
Prostaglandin Analog, Timolol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Bosentan on Exercise Capacity at High Altitude

NCT00432978
View directory record Official record
Conditions
Altitude, Pulmonary Hypertension
Interventions
Bosentan administration
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2007 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prenatal Mindfulness & Hypertension Study

NCT03679117
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Mindfulness Training
Behavioral
Lead sponsor
Lifespan
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV

NCT04661813
View directory record Official record
Conditions
HIV-1-infection, Hypertension
Interventions
EXTRA-CVD Virtual Care
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 17, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

NCT01172496
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 17, 2026, 10:29 PM EDT